Capital Group Private Client Services Inc. Lowers Stock Position in Merck & Co., Inc. $MRK

Capital Group Private Client Services Inc. trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 94.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,641 shares of the company’s stock after selling 90,339 shares during the quarter. Capital Group Private Client Services Inc.’s holdings in Merck & Co., Inc. were worth $473,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Darwin Wealth Management LLC raised its stake in shares of Merck & Co., Inc. by 237.4% during the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after buying an additional 216 shares during the last quarter. Kilter Group LLC purchased a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at about $27,000. Bare Financial Services Inc raised its stake in shares of Merck & Co., Inc. by 51.9% during the 2nd quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock worth $29,000 after buying an additional 125 shares during the period. Barnes Dennig Private Wealth Management LLC lifted its position in shares of Merck & Co., Inc. by 302.3% in the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock valued at $30,000 after acquiring an additional 266 shares in the last quarter. Finally, Evolution Wealth Management Inc. acquired a new stake in Merck & Co., Inc. during the 2nd quarter worth $31,000. Institutional investors own 76.07% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on MRK. Bank of America raised their price objective on Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Zacks Research lowered Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a report on Friday, January 9th. Citigroup boosted their target price on Merck & Co., Inc. from $115.00 to $120.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Barclays assumed coverage on Merck & Co., Inc. in a report on Friday, February 20th. They set an “overweight” rating and a $140.00 price target on the stock. Finally, Guggenheim increased their target price on Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus price target of $125.88.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Positive late‑stage clinical results across oncology and HIV programs — Phase 3 data for KEYTRUDA and WELIREG showed improved survival/expanded indications in kidney, ovarian and bladder cancer, and Merck highlighted progress on its DOR/ISL HIV program; these outcomes support revenue growth potential from high‑margin specialty drugs. Merck Trial Wins Shape Oncology And HIV Prospects For Investors
• Positive Sentiment: Recent earnings and guidance remain supportive — Merck posted an EPS beat and set FY2026 guidance, which underpins expectations for profitability and cash generation that fund R&D, buybacks, and dividends. (Earnings referenced from Merck’s Feb results.)
• Neutral Sentiment: Broader market reports note expanding markets for several of Merck’s products (neuroendocrine carcinoma, vaccines like Ervebo, M‑M‑R II, and fertility drug Elonva); these reports signal longer‑term TAM expansion but are not near‑term catalysts by themselves. Neuroendocrine Carcinoma Market Poised for Significant Growth Ervebo (Merck & Co) Market Research Report 2026 M-M-R II (Merck & Co) Market Research Report 2026 Elonva (Merck & Co) Market Research Report 2026
• Neutral Sentiment: Short‑term price momentum: recent coverage noted MRK moving higher within the S&P 500 and outperforming the market on some sessions — useful context for market positioning but not a fundamental change. Merck & Co. Moves Higher Within S&P 500 Index Amid Gains Merck (MRK) Rises Higher Than Market: Key Facts
• Negative Sentiment: Analyst caution on Winrevair — RBC flagged that Winrevair needs to show at least a 20‑meter improvement on the 6‑minute walk test to build confidence; failure to meet clinically meaningful thresholds could weigh on sentiment for that respiratory program. Merck’s Winrevair Must Show Walk Distance Improvement to Build Confidence, RBC Says

Merck & Co., Inc. Stock Down 0.7%

Merck & Co., Inc. stock opened at $116.21 on Thursday. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14. The firm has a market capitalization of $287.32 billion, a price-to-earnings ratio of 15.96, a price-to-earnings-growth ratio of 2.27 and a beta of 0.27. The stock’s fifty day moving average is $114.86 and its two-hundred day moving average is $99.26. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. The firm had revenue of $16.40 billion for the quarter, compared to analysts’ expectations of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The firm’s revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the company earned $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 46.70%.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, CMO Chirfi Guindo sold 10,000 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $118.41, for a total transaction of $1,184,100.00. Following the transaction, the chief marketing officer owned 70,615 shares in the company, valued at $8,361,522.15. The trade was a 12.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Richard R. Deluca sold 37,685 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the sale, the executive vice president owned 160,174 shares in the company, valued at $19,368,240.08. This represents a 19.05% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 320,176 shares of company stock worth $38,281,735. Company insiders own 0.13% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.